Achim Aigner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3726065/publications.pdf

Version: 2024-02-01

170	9,169	38742 50	45317 90
papers	citations	h-index	g-index

175	175	175	11587
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Therapy, 2005, 12, 461-466.	4.5	660
2	MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma. Cancer Research, 2011, 71, 5214-5224.	0.9	358
3	Poly(vinyl alcohol) Nanofibers by Electrospinning as a Protein Delivery System and the Retardation of Enzyme Release by Additional Polymer Coatings. Biomacromolecules, 2005, 6, 1484-1488.	5.4	329
4	Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin. Journal of Biological Chemistry, 2001, 276, 16772-16779.	3.4	325
5	A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. Journal of Controlled Release, 2006, 112, 257-270.	9.9	265
6	RNA Interference-Mediated Gene Silencing of Pleiotrophin Through Polyethylenimine-Complexed Small Interfering RNAsIn VivoExerts Antitumoral Effects in Glioblastoma Xenografts. Human Gene Therapy, 2006, 17, 751-766.	2.7	229
7	A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Medicine, 1997, 3, 1137-1140.	30.7	225
8	Liposomeâ€“polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials, 2010, 31, 6892-6900.	11.4	183
9	Gene silencing through RNA interference (RNAi) in vivo: Strategies based on the direct application of siRNAs. Journal of Biotechnology, 2006, 124, 12-25.	3.8	181
10	In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(â€“PEG)/siRNA complexes. Toxicology and Applied Pharmacology, 2009, 236, 97-108.	2.8	178
11	Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. Nature Cell Biology, 2014, 16, 779-791.	10.3	174
12	Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 438-449.	4.3	166
13	Polyethylenimines for <scp>siRNA</scp> and <scp>miRNA</scp> delivery in vivo. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2013, 5, 484-501.	6.1	166
14	Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth. Journal of Biological Chemistry, 2002, 277, 14153-14158.	3.4	153
15	From the exposome to mechanistic understanding of chemical-induced adverse effects. Environment International, 2017, 99, 97-106.	10.0	146
16	PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. Journal of Drug Targeting, 2008, 16, 124-139.	4.4	144
17	The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer, 2008, 59, 12-23.	2.0	138
18	Enhancement of Fibroblast Growth Factor (FGF) Activity by an FGF-binding Protein. Journal of Biological Chemistry, 2001, 276, 40247-40253.	3.4	128

#	Article	IF	Citations
19	MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. Journal of Molecular Medicine, 2011, 89, 445-457.	3.9	128
20	Matrix Metalloproteinases 2 and 9 Mediate Epidermal Growth Factor Receptor Transactivation by Gonadotropin-releasing Hormone. Journal of Biological Chemistry, 2003, 278, 47307-47318.	3.4	116
21	Hyperbranched PEI with Various Oligosaccharide Architectures: Synthesis, Characterization, ATP Complexation, and Cellular Uptake Properties. Biomacromolecules, 2009, 10, 1114-1124.	5.4	116
22	Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Applied Microbiology and Biotechnology, 2007, 76, 9-21.	3.6	112
23	The proto-oncogene Pim-1 is a target of miR-33a. Oncogene, 2012, 31, 918-928.	5.9	109
24	Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce Î±-Synuclein Expression in a Model of Parkinsonâ€™s Disease. Molecular Therapy - Nucleic Acids, 2017, 9, 57-68.	5.1	105
25	HMGA2 gene is a promising target for ovarian cancer silencing therapy. International Journal of Cancer, 2008, 123, 348-356.	5.1	102
26	Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): Physicochemical and biological properties of DNA and siRNA complexes. Journal of Controlled Release, 2011, 149, 146-158.	9.9	101
27	Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo. Journal of Controlled Release, 2020, 319, 63-76.	9.9	101
28	Delivery Systems for the Direct Application of siRNAs to Induce RNA Interference (RNAi) In Vivo. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-15.	3.0	100
29	Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Therapy, 2002, 9, 1700-1707.	4.5	97
30	Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers, 2021, 13, 634.	3.7	96
31	Polyethylenimine/small interfering RNAâ€mediated knockdown of vascular endothelial growth factor in vivo exerts antiâ€tumor effects synergistically with Bevacizumab. Journal of Gene Medicine, 2010, 12, 287-300.	2.8	95
32	CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut, 2010, 59, 1101-1110.	12.1	93
33	Physicochemical and Biological Characterization of Polyethylenimine-graft-Poly(ethylene glycol) Block Copolymers as a Delivery System for Oligonucleotides and Ribozymes. Bioconjugate Chemistry, 2004, 15, 677-684.	3.6	88
34	Nanoparticles for radiooncology: Mission, vision, challenges. Biomaterials, 2017, 120, 155-184.	11.4	87
35	The fibroblast growth factor-binding protein FGF-BP. International Journal of Biochemistry and Cell Biology, 2006, 38, 1463-1468.	2.8	84
36	Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma. Neoplasia, 2013, 15, 783-IN28.	5.3	84

#	Article	IF	Citations
37	Expression and Function of the Receptor Protein Tyrosine Phosphatase Î¶ and Its Ligand Pleiotrophin in Human Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1265-1275.	1.7	83
38	Cellular Delivery In Vivo of siRNA-Based Therapeutics. Current Pharmaceutical Design, 2008, 14, 3603-3619.	1.9	79
39	Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemotherapy and Pharmacology, 2011, 67, 1157-1166.	2.3	77
40	Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 29-41.	4.3	72
41	An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. International Journal of Cancer, 2001, 92, 510-517.	5.1	65
42	Storage stability of optimal liposomeâ€“polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery. Acta Biomaterialia, 2014, 10, 2663-2673.	8.3	65
43	Stabilization of oligonucleotideâ€“polyethylenimine complexes by freeze-drying: physicochemical and biological characterization. Journal of Controlled Release, 2004, 95, 119-131.	9.9	61
44	RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro-Oncology, 2011, 13, 1074-1089.	1.2	60
45	Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy. Acta Biomaterialia, 2014, 10, 2965-2975.	8.3	58
46	A novel tyrosine-modified low molecular weight polyethylenimine (P10Y) for efficient siRNA delivery in vitro and in vivo. Journal of Controlled Release, 2016, 230, 13-25.	9.9	58
47	Polyethylenimine (PEI)/siRNA-Mediated Gene Knockdown In Vitro and In Vivo. Methods in Molecular Biology, 2010, 623, 283-297.	0.9	56
48	Enhanced Antitumorigenic Effects in Glioblastoma on Double Targeting of Pleiotrophin and Its Receptor ALK. Neoplasia, 2009, 11, 145-156.	5.3	55
49	Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 209-218.	3.3	55
50	Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment. Pharmaceutics, 2021, 13, 1135.	4.5	55
51	Stimulation of the chemosensory TRPA1 cation channel by volatile toxic substances promotes cell survival of small cell lung cancer cells. Biochemical Pharmacology, 2013, 85, 426-438.	4.4	54
52	Expression of a truncated 100â€‰kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene, 2001, 20, 2101-2111.	5.9	53
53	Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Medicine, 2016, 5, 1444-1453.	2.8	50
54	Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. British Journal of Cancer, 2002, 86, 858-863.	6.4	49

#	Article	IF	Citations
55	Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Annals of Oncology, 2003, 14, 1525-1529.	1.2	49
56	Nucleic acid delivery with extracellular vesicles. Advanced Drug Delivery Reviews, 2021, 173, 89-111.	13.7	48
57	Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogeneâ€induced senescence. EMBO Molecular Medicine, 2013, 5, 1367-1382.	6.9	45
58	Up-regulation of a fibroblast growth factor binding protein in children with renal diseases. Kidney International, 2001, 59, 1717-1728.	5.2	44
59	Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy. Current Gene Therapy, 2014, 14, 343-351.	2.0	44
60	Efficiency of polyethylenimines and polyethylenimine-graft-poly (ethylene glycol) block copolymers to protect oligonucleotides against enzymatic degradation. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 427-430.	4.3	41
61	Nonviral in vivo delivery of therapeutic small interfering RNAs. Current Opinion in Molecular Therapeutics, 2007, 9, 345-52.	2.8	41
62	Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochemistry and Cell Biology, 2002, 117, 1-11.	1.7	40
63	Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model. Drug Delivery and Translational Research, 2017, 7, 206-216.	5.8	40
64	Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner. Neoplasia, 2015, 17, 564-573.	5.3	39
65	A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA. Small, 2017, 13, 1700072.	10.0	39
66	Sprayâ€Dried Nanoparticleâ€inâ€Microparticle Delivery Systems (NiMDS) for Gene Delivery, Comprising Polyethylenimine (PEI)â€Based Nanoparticles in a Poly(Vinyl Alcohol) Matrix. Small, 2018, 14, e1701810.	10.0	38
67	Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene, 2002, 21, 5733-5742.	5.9	35
68	Differential Regulation of a Fibroblast Growth Factor-Binding Protein during Skin Carcinogenesis and Wound Healing. Neoplasia, 2004, 6, 595-602.	5.3	35
69	Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. International Journal of Cancer, 2005, 117, 942-951.	5.1	35
70	Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Research, 2003, 63, 8085-9.	0.9	34
71	Critical Role of GÎ±12 and GÎ±13 for Human Small Cell Lung Cancer Cell Proliferation In vitro and Tumor Growth In vivo. Clinical Cancer Research, 2010, 16, 1402-1415.	7.0	33
72	Ricin and Ricinus communis in pharmacology and toxicology-from ancient use and â€œPapyrus Ebersâ€to modern perspectives and â€œpoisonous plant of the year 2018â€. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 1181-1208.	3.0	33

#	Article	IF	Citations
73	Expression of Pleiotrophin and its Receptors in Human Placenta Suggests Roles in Trophoblast Life Cycle and Angiogenesis. Placenta, 2009, 30, 649-653.	1.5	32
74	MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy. Current Pharmaceutical Design, 2012, 19, 1242-1252.	1.9	32
75	The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival. EMBO Molecular Medicine, 2013, 5, 919-934.	6.9	31
76	Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. Toxicology, 2000, 144, 221-228.	4.2	30
77	Biocompatibility and Efficacy of Oligomaltose-Grafted Poly(ethylene imine)s (OM-PEIs) for in Vivo Gene Delivery. Molecular Pharmaceutics, 2013, 10, 4666-4675.	4.6	30
78	Microparticulate poly(vinyl alcohol) hydrogel formulations for embedding and controlled release of polyethylenimine (PEI)-based nanoparticles. Acta Biomaterialia, 2016, 45, 210-222.	8.3	30
79	Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochemical and Biophysical Research Communications, 2004, 321, 403-412.	2.1	29
80	Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma. Molecular Cancer, 2011, 10, 144.	19.2	29
81	Analysis of Transcriptional Regulation of the Human miR-17-92 Cluster; Evidence for Involvement of Pim-1. International Journal of Molecular Sciences, 2013, 14, 12273-12296.	4.1	29
82	The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma. Oncogene, 2017, 36, 3464-3476.	5.9	29
83	ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. , 2000, 86, 644-651.		28
84	Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?. Nanomedicine, 2018, 13, 89-103.	3.3	28
85	In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. Toxicology in Vitro, 2009, 23, 500-508.	2.4	27
86	A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models. Clinical and Experimental Metastasis, 2010, 27, 261-271.	3.3	25
87	Multiple effects of the special ATâ€rich binding protein 1 (SATB1) in colon carcinoma. International Journal of Cancer, 2014, 135, 2537-2546.	5.1	25
88	Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo. Cancer Letters, 2011, 304, 128-136.	7.2	24
89	Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics. Cancer Chemotherapy and Pharmacology, 2014, 73, 827-837.	2.3	24
90	Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. Clinical Colorectal Cancer, 2018, 17, e189-e199.	2.3	24

#	Article	IF	Citations
91	Polymeric Nanoparticles Based on Tyrosine-Modified, Low Molecular Weight Polyethylenimines for siRNA Delivery. Pharmaceutics, 2019, 11, 600.	4.5	24
92	Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R775-R783.	1.8	23
93	Nanoparticles for local delivery of siRNA in lung therapy. Advanced Drug Delivery Reviews, 2021, 179, 114038.	13.7	23
94	The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors. Cancer Letters, 2018, 417, 96-111.	7.2	22
95	Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model. Cancers, 2019, 11, 333.	3.7	22
96	Antigen specific immune response inChlamydia muridarumgenital infection is dependent on murine microRNAs-155 and -182. Oncotarget, 2016, 7, 64726-64742.	1.8	22
97	Rat. Growth Factors, 2000, 18, 51-62.	1.7	21
98	PEI-complexed LNA antiseeds as miRNA inhibitors. RNA Biology, 2012, 9, 1088-1098.	3.1	21
99	Biokinetic studies of non-complexed siRNA versus nano-sized PEI F25-LMW/siRNA polyplexes following intratracheal instillation into mice. International Journal of Pharmaceutics, 2016, 500, 227-235.	5.2	21
100	Transport and Detoxication: Principles, Approaches, and Perspectives for Research on the Bloodâ€“ Brain Barrier. Angewandte Chemie International Edition in English, 1997, 36, 24-41.	4.4	20
101	A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 711-715.	4.3	19
102	A Novel Method for the Assessment of Targeted PEI-Based Nanoparticle Binding Based on a Static Surface Plasmon Resonance System. Analytical Chemistry, 2014, 86, 6827-6835.	6.5	19
103	Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 371, 141-151.	3.0	18
104	Influence of nanoparticle-mediated transfection on proliferation of primary immune cells in vitro and in vivo. PLoS ONE, 2017, 12, e0176517.	2.5	18
105	The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes. Oncogene, 2001, 20, 7430-7436.	5.9	17
106	Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma. Pharmaceuticals, 2011, 4, 1591-1606.	3.8	17
107	Degradable and Biocompatible Poly(N ,N -dimethylaminoethyl Methacrylate-co) Tj ETQq1 1 0.784314 rgBT /Over	4.1	17
108	Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells InÂVitro and InÂVivo. Molecular Therapy - Nucleic Acids, 2019, 16, 272-283.	5.1	17

#	Article	IF	Citations
109	Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma. Journal of Nanobiotechnology, 2020, 18, 173.	9.1	17
110	Tyrosine-Modification of Polypropylenimine (PPI) and Polyethylenimine (PEI) Strongly Improves Efficacy of siRNA-Mediated Gene Knockdown. Nanomaterials, 2020, 10, 1809.	4.1	17
111	Tumor tissue slice cultures as a platform for analyzing tissue-penetration and biological activities of nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 45-50.	4.3	16
112	Perspectives, issues and solutions in RNAi therapy: the expected and the less expected. Nanomedicine, 2019, 14, 2777-2782.	3.3	16
113	The combined disulfide cross-linking and tyrosine-modification of very low molecular weight linear PEI synergistically enhances transfection efficacies and improves biocompatibility. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 161, 56-65.	4.3	16
114	Tyrosine-modified linear PEIs for highly efficacious and biocompatible siRNA delivery in vitro and in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 36, 102403.	3.3	16
115	Sustained delivery of siRNA poly- and lipopolyplexes from porous macromer-crosslinked gelatin gels. International Journal of Pharmaceutics, 2017, 526, 178-187.	5.2	15
116	The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer. Cancers, 2020, 12, 1122.	3.7	15
117	Nebulization of liposomeâ€“polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery: Physicochemical properties and biological activity. European Journal of Lipid Science and Technology, 2014, 116, 1195-1204.	1.5	14
118	TRPM7 is a molecular substrate of ATP-evoked P2X7-like currents in tumor cells. Journal of General Physiology, 2016, 147, 467-483.	1.9	14
119	A new player in the game: treatment with antagomiR-21a-5p significantly attenuates histological and echocardiographic effects of experimental autoimmune myocarditis. Cardiovascular Research, 2022, 118, 556-572.	3.8	14
120	Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies. International Journal of Clinical Pharmacology and Therapeutics, 2020, 58, 426-438.	0.6	14
121	Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation. Drug Design, Development and Therapy, 2018, Volume 12, 3653-3664.	4.3	13
122	Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors. Pharmaceutics, 2021, 13, 676.	4.5	13
123	Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression. Journal of Experimental and Clinical Cancer Research, 2021, 40, 214.	8.6	13
124	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. Frontiers in Bioengineering and Biotechnology, 2022, 10, 801870.	4.1	13
125	Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells. BMC Cancer, 2017, 17, 3.	2.6	12
126	Transfection of primary brain capillary endothelial cells for protein synthesis and secretion of recombinant erythropoietin: a strategy to enable protein delivery to the brain. Cellular and Molecular Life Sciences, 2017, 74, 2467-2485.	5.4	12

#	Article	IF	Citations
127	Inhibition of PIM2 in liver cancer decreases tumor cell proliferation inï¿½vitro and inï¿½vivo primarily through the modulation of cell cycle progression. International Journal of Oncology, 2020, 56, 448-459.	3.3	12
128	Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice. NAR Cancer, 2020, 2, zcaa014.	3.1	12
129	Role of Chemosensory TRP Channels in Lung Cancer. Pharmaceuticals, 2018, 11, 90.	3.8	11
130	Design, synthesis and biological evaluation of Î²-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity. MedChemComm, 2019, 10, 1109-1115.	3.4	11
131	Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells. Histochemistry and Cell Biology, 2020, 153, 367-377.	1.7	10
132	Restoration of MARCK enhances chemosensitivity in cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 843-858.	2.5	10
133	Anti-CD3 Antibody Treatment Reduces Scar Formation in a Rat Model of Myocardial Infarction. Cells, 2020, 9, 295.	4.1	10
134	miR24â€“3p activity after delivery into pancreatic carcinoma cell lines exerts profound tumor-inhibitory effects through distinct pathways of apoptosis and autophagy induction. Cancer Letters, 2021, 503, 174-184.	7.2	10
135	Balancing Histone Deacetylase (HDAC) Inhibition and Drugâ€likeness: Biological and Physicochemical Evaluation of ClassÂI Selective HDAC Inhibitors. ChemMedChem, 2022, , .	3.2	10
136	U1 Adaptors for the Therapeutic Knockdown of the Oncogene Pim-1 Kinase in Glioblastoma. Nucleic Acid Therapeutics, 2013, 23, 264-272.	3.6	9
137	A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity inÂMelanoma. Journal of Investigative Dermatology, 2016, 136, 2475-2484.	0.7	9
138	Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2. Future Oncology, 2009, 5, 13-17.	2.4	8
139	SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC). Scientific Reports, 2020, 10, 8615.	3.3	8
140	Unmodified and tyrosine-modified polyethylenimines as potential carriers for siRNA: Biophysical characterization and toxicity. International Journal of Pharmaceutics, 2022, 614, 121468.	5.2	8
141	Cationic Lipid-Coated Polyplexes (Lipopolyplexes) for DNA and Small RNA Delivery. Methods in Molecular Biology, 2016, 1445, 187-200.	0.9	7
142	Mono- and Polyassociation Processes of Pentavalent Biotinylated PEI Glycopolymers for the Fabrication of Biohybrid Structures with Targeting Properties. Biomacromolecules, 2019, 20, 3408-3424.	5.4	7
143	Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects. Scientific Reports, 2019, 9, 15471.	3.3	7
144	Therapeutic miR-506-3p Replacement in Pancreatic Carcinoma Leads to Multiple Effects including Autophagy, Apoptosis, Senescence, and Mitochondrial Alterations In Vitro and In Vivo. Biomedicines, 2022, 10, 1692.	3.2	7

#	Article	IF	Citations
145	Glioblastoma Tissue Slice Tandem-Cultures for Quantitative Evaluation of Inhibitory Effects on Invasion and Growth. Cancers, 2020, 12, 2707.	3.7	6
146	Tetraspanin 5 (TSPAN5), a Novel Gatekeeper of the Tumor Suppressor DLC1 and Myocardin-Related Transcription Factors (MRTFs), Controls HCC Growth and Senescence. Cancers, 2021, 13, 5373.	3.7	6
147	STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death. Cancers, 2022, 14, 339.	3.7	6
148	Amphiphilic Anionic Oligomer-Stabilized Calcium Phosphate Nanoparticles with Prospects in siRNA Delivery via Convection-Enhanced Delivery. Pharmaceutics, 2022, 14, 326.	4.5	6
149	Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA. Expert Opinion on Biological Therapy, 2009, 9, 1533-1542.	3.1	5
150	Evaluation of Colon-Specific Plasma Nanovesicles as New Markers of Colorectal Cancer. Cancers, 2021, 13, 3905.	3.7	5
151	Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases. Carcinogenesis, 2021, 42, 1475-1484.	2.8	5
152	Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers. Cancers, 2022, 14, 208.	3.7	5
153	Tumor-targeting nanosystems for the delivery of siRNA. Nanomedicine, 2007, 2, 569-572.	3.3	3
154	Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy. Cells, 2021, 10, 272.	4.1	3
155	Polymer-Based Delivery of RNA-Based Therapeutics in Ovarian Cancer. Methods in Molecular Biology, 2013, 1049, 443-465.	0.9	3
156	SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 82.	4.1	3
157	Non-viral siRNA transfection of primary mesenchymal stromal cells (MSCs): Assessment of tyrosine-modified PEI and PPI efficacy and biocompatibility. International Journal of Pharmaceutics, 2022, 612, 121359.	5.2	3
158	Regioselective Ringâ€Opening Polymerization of a Polyhydroxycarboxylic Acid for the Synthesis of a Nanoscale Carrier Material with pHâ€Dependent Stability and Sustained Drug Release. Angewandte Chemie - International Edition, 2015, 54, 6364-6369.	13.8	2
159	Ribozyme Targeting of Angiogenic Molecules. , 1999, , 423-441.		2
160	Characterization of Drug Release from Mesoporous SiO2-Based Membranes with Variable Pore Structure and Geometry. Pharmaceutics, 2022, 14, 1184.	4.5	2
161	Biokinetic datasets of PEI F25-LMW complexed and non-complexed 32P-siRNA within different lung compartments. Data in Brief, 2016, 7, 1175-1178.	1.0	1
162	Controlled Release Technologies for RNAi Strategies in Regenerative Medicine. , 2016, , 185-210.		1

#	Article	IF	Citations
163	Targeted Transposition of Minicircle DNA Using Single-Chain Antibody Conjugated Cyclodextrin-Modified Poly (Propylene Imine) Nanocarriers. Cancers, 2022, 14, 1925.	3.7	1
164	Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers. PLoS ONE, 2022, 17, e0266897.	2.5	1
165	RNA Interference-Mediated Gene Silencing of Pleiotrophin Through Polyethylenimine-Complexed Small Interfering RNAs In Vivo Exerts Antitumoral Effects in Glioblastoma Xenografts. Human Gene Therapy, 2006, .	2.7	0
166	Nanosystems for the Delivery of RNAi. , 2009, , 197-220.		0
167	Verminderung der Genexpression Ã¼ber Ribozym-Targeting. , 2012, , 455-465.		0
168	Organotypic slice cultures of human gastric cancer (GC) and esophagogastric junction adenocarcinoma (AEG): A new technology to study treatment response, resistance, and tumor heterogeneity.. Journal of Clinical Oncology, 2015, 33, 76-76.	1.6	0
169	Abstract 301: RealTVac, a novel strategy to treat advanced, late-stage tumors with real-time tumor vaccination. , 2015, , .		0
170	TRPM7 is a molecular substrate of ATP-evoked P2X7-like currents in tumor cells. Journal of Cell Biology, 2016, 213, 2135OIA112.	5.2	0